Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial of Novel Epothilone BMS-247550 Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant

NCT00080301 is registered in ClinicalTrials.gov with R-Pharm as lead sponsor.

NCT NCT00080301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00080301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial of Novel Epothilone BMS-247550 Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant
Lead sponsor
R-Pharm
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2003
Completion date
March 31, 2008
Enrollment
752 (actual)
Sites
127

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastases